Edition:
United States

Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

2,181JPY
22 Jan 2018
Change (% chg)

¥22 (+1.02%)
Prev Close
¥2,159
Open
¥2,158
Day's High
¥2,181
Day's Low
¥2,147
Volume
526,100
Avg. Vol
1,125,705
52-wk High
¥2,328
52-wk Low
¥1,515

Latest Key Developments (Source: Significant Developments)

Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex
Thursday, 4 Jan 2018 01:40am EST 

Jan 4(Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd <<<4217.T>>>, on Jan. 4 .  Full Article

Kyowa Hakko Kirin says change of chairman and president
Friday, 22 Dec 2017 01:37am EST 

Dec 22 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T> ::Says it appoints current president and CEO Nobuo Hanai as new chairman and CEO, Masashi Miyamoto as new president .Changes will be effective on the day of ordinary general meeting of shareholders scheduled in March 2018.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 05:20pm EST 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Kyowa Hakko Kirin Announces FDA Acceptance For Filing And Priority Review Designation Of Mogamulizumab's Biologics License Application
Tuesday, 28 Nov 2017 05:00am EST 

Nov 28 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::KYOWA HAKKO KIRIN ANNOUNCES FDA ACCEPTANCE FOR FILING AND PRIORITY REVIEW DESIGNATION OF MOGAMULIZUMAB'S BIOLOGICS LICENSE APPLICATION.  Full Article

Kyowa Hakko Kirin says voluntary adoption of International Financial Reporting Standards (IFRS)
Thursday, 26 Oct 2017 03:13am EDT 

Oct 26 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it plans to adopt International Financial Reporting Standards (IFRS) as the new accounting method, to replace the Japanese Generally Accepted Accounting Principles .The change is to be implemented in its consolidated financial statements for the fiscal year ending December 31, 2017.  Full Article

ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION
Tuesday, 10 Oct 2017 08:30am EDT 

Oct 10 (Reuters) - Ultragenyx Pharmaceutical Inc ::ULTRAGENYX AND KYOWA HAKKO KIRIN ANNOUNCE FDA ACCEPTANCE AND PRIORITY REVIEW DESIGNATION OF BUROSUMAB’S BIOLOGICS LICENSE APPLICATION.ULTRAGENYX PHARMACEUTICAL INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE FOR BLA IS APRIL 17, 2018​.ULTRAGENYX PHARMACEUTICAL INC - FDA HAS NOT INFORMED COMPANIES WHETHER AN ADVISORY COMMITTEE MEETING TO DISCUSS APPLICATION WILL BE NEEDED​.ULTRAGENYX - FDA ACCEPTED BLA FOR BUROSUMAB TO TREAT PEDIATRIC, ADULT PATIENTS WITH X-LINKED HYPOPHOSPHATEMIA, GRANTED PRIORITY REVIEW STATUS​.  Full Article

Kyowa Hakko Kirin to sell part of stake in unit Kyowa Medex
Friday, 29 Sep 2017 03:07am EDT 

Sept 29(Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says it will sell a part of stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd.<<<4217.T>>>.Price undetermined .Says the company will cut stake in Kyowa Medex to 33.4 percent .Transaction date on Jan. 4, 2018.  Full Article

R&I affirms Kyowa Hakko Kirin's rating at "A+" and announces stable outlook -R&I
Friday, 25 Aug 2017 02:58am EDT 

Aug 25(Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+" -R&I.Rating outlook stable -R&I.  Full Article

Kyowa Hakko Kirin says U.S. FDA grants breakthrough therapy designation for Mogamulizumab
Friday, 25 Aug 2017 02:30am EDT 

Aug 25 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T> - :US Food and Drug Administration grants breakthrough therapy designation for Mogamulizumab for the treatment of Mycosis Fungoides and Sézary Syndrome.Initiated discussions with other regulatory authorities concerning plans for marketing authorization applications for Mogamulizumab in CTCL.  Full Article

Sumitomo Chemical buys Kyowa Hakko's agrochemical segment - Nikkei
Thursday, 3 Aug 2017 04:19pm EDT 

Aug 4 (Reuters) - Nikkei::Sumitomo Chemical Co Ltd to buy Kyowa Hakko Kirin's agrochemical segment in deal valued at 6 billion yen to 7 billion yen .Sumitomo Chemical will take in 10 to 20 employees from operation, production facilities to remain under Kyowa Hakko's wing .  Full Article

BRIEF- Kyowa Hakko Kirin sells 66.6 pct stake in unit Kyowa Medex

* Says it sold 66.6 percent stake in wholly owned unit Kyowa Medex Co., Ltd., to Hitachi Chemical Company, Ltd, on Jan. 4